Mangoceuticals (NASDAQ:MGRX) & Acadia Healthcare (NASDAQ:ACHC) Head to Head Comparison

Mangoceuticals (NASDAQ:MGRX) and Acadia Healthcare (NASDAQ:ACHC) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Risk & Volatility

Mangoceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Acadia Healthcare has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

Institutional & Insider Ownership

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 1.2% of Acadia Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Mangoceuticals and Acadia Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
Acadia Healthcare	-33.44%	6.19%	2.42%

Analyst Ratings

This is a breakdown of current ratings for Mangoceuticals and Acadia Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1	0	0	0	1.00
Acadia Healthcare	2	5	7	1	2.47

Acadia Healthcare has a consensus price target of $29.85, suggesting a potential upside of 5.99%. Given Acadia Healthcare’s stronger consensus rating and higher possible upside, analysts clearly believe Acadia Healthcare is more favorable than Mangoceuticals.

Valuation and Earnings

This table compares Mangoceuticals and Acadia Healthcare”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460,000.00	21.21	-$20.64 million	($1.01)	-0.45
Acadia Healthcare	$3.31 billion	0.79	-$1.10 billion	($12.45)	-2.26

Mangoceuticals has higher earnings, but lower revenue than Acadia Healthcare. Acadia Healthcare is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Acadia Healthcare beats Mangoceuticals on 8 of the 15 factors compared between the two stocks.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

About Acadia Healthcare

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.